State Legislators Seek To Broaden Regulation Of Biotech Products

Scientists fear that a patchwork of local laws more stringent than federal restrictions may hamper research and industry As state legislatures throughout the United States take steps to intensify their participation in biotechnology regulation, some states are enacting restrictions on the use of biotechnological products. In some cases, these laws go beyond limits already put in place by the federal government. While legislators say they believe that such regulation protects their states' eco

Written byRobin Eisner
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

While legislators say they believe that such regulation protects their states' economic and public safety interests, some scientists say that more restrictive regulations may inhibit industrial and academic scientists from doing research in these states.

"It becomes dismotivating and expensive for the business when there are too many differences across the states," says Jerry Barnett, director of government affairs for Monsanto Agricultural Co. in St. Louis. "It is not that we as an industry are opposing legislation at a state level, but we hope [the states] participate in what is a very comprehensive federal regulatory system."

It was 1984 when the Environmental Protection Agency issued its first permit for a release of genetically engineered "ice-minus" bacteria, which lower the temperature at which strawberry plants freeze, into Monterey County, Calif. Since then, about 200 more field tests of genetically engineered organisms have occurred in the U.S. with permission from three main ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies